- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023
The seasonal respiratory syncytial virus, which claims between 6000 and 10 000 older adult lives each year, will now face significant barriers to spread in this vulnerable population the US.
The short slide show that follows provides snapshots of the headline news stories posted on Patient Care® in 2023 that traced the clinical trials and approval process for GKS's RSVPreF3 (Arexvy) and Pfizer's RSVPreF (Abrysvo).
In 2023, after more than 50 years of research to create the antigen that would safely elicit the most robust immune response to the virus, 2 pharmaceutical companies, within a month of each other, were granted US Food and Drug Administration approval for a vaccines against the virus: GSK for in for RSVPreF3 (Arexvy) and Pfizer for RSVPreF (Abrysvo). Both are indicated for adults aged 60 years and older based on shared decision making with their health care provider. The CDC strongly recommends a single shot for older adults with certain chronic conditions that put them at high risk for severe disease.
Related Videos
The "Ugly Face" of Long COVID: A Conversation with Steven Flanagan, MD, President-elect, AAPM&R
Persistent Vaccine Skepticism Can Erode Clinician Confidence in their Own Recommendations
"Vaccination is More of a Marathon than a Sprint, so Keep Listening”
Booster Fatigue, Vaccines are for Kids, and Other Obstacles to Adult Immunization in Primary Care
Vaccine Hesitancy: How COVID-19 Changed the Tone, with Gretchen LaSalle, MD
Immunization Action Coalition President and Flu Expert Dr Kelly Moore Explains Primary Care's "Tall Order"
Related Content
